Stemline Therapeutics (STML) Misses Q1 EPS by 10c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. DAL

Go back to Stemline Therapeutics (STML) Misses Q1 EPS by 10c, Revenues Beat

Stemline Therapeutics Reports First Quarter 2019 Financial Results

May 10, 2019 6:30 AM EDT

Net revenue for ELZONRIS was $5.05 million for the first quarterConference call and live webcast scheduled for today at 8:00 AM ET

NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today reported financial results and business highlights for the first quarter ended March 31, 2019.

Since ELZONRIS became commercially available in January, we have been very pleased with the progress we have made executing our launch plan, stated Robert Francomano, SVP and... More